Keeping patients out of care facilities— clozapine rescues Parkinson’s patients with troublesome psychosis unresponsive to quetiapine and pimavanserin.
Objective: We describe a single-center cohort of Parkinson patients in crisis with troublesome psychosis unresponsive to quetiapine and pimavanserin, who were rescued by treatment with…How does a diagnosis of Dementia with Parkinson’s influence future care provision?
Objective: To describe the trajectory of Parkinson’s after the onset of dementia including setting of care, frailty levels and mortality rate. Background: Cardiff and Vale…Fibrinogen and CFAH: The two putative markers of Parkinson’s disease with cognitive impairment
Objective: To determine the pathogenic potential of fibrinogen and complement factor H (CFAH) in causing Parkinson’s disease (PD) with cognitive impairment (PDCI)-like symptoms using C57BL/6J…Predicting the development of dementia in patients with Parkinson’s disease by comparing neurosteroids in the blood level
Objective: To increase the reliability of the development of dementia in patients with PD by a comparative assessment of clinical scales and neurosteroids Background: Parkinson's…Data-driven identification of distinct fronto-subcortical and cortical-posterior subtypes of cognitive decline in Parkinson’s disease
Objective: To use a novel data-driven approach, Subtype and Stage inference (SuStain)[1], for identifying distinct subtypes of domain-specific cognitive decline in Parkinson’s disease (PD), and…Lewy body disease clinical subgroups present similar disease progression rates
Objective: To characterize LBD clinical subgroups and identify possible differences in disease progression. Background: Patients with Lewy body disease (LBD) present a wide variety of…The East London Parkinson Disease Project – engaging a diverse population in research
Objective: The objective of this study was to engage a diverse group of people with Parkinson disease (PwP) from East London and build a research…Plasma Alzheimer’s disease biomarkers and cognitive progression in Parkinson’s disease
Objective: To evaluate the relationship between plasma Alzheimer's disease biomarkers and cognitive progression in Parkinson's disease Background: Plasma phosphorylated tau (ptau) isoforms have been recently…Early-onset Dementia with Lewy Bodies and Parkinson’s Disease Dementia: A Population-based Study (2010-2015).
Objective: To examine the incidence, clinical features, and survival of early-onset Dementia with Lewy Bodies and Parkinson’s Disease Dementia (DLB/PDD) (≤55 years of age) in…A Phase 2 Randomized Controlled Trial Repurposing Ambroxol as a Disease Modifying Treatment for Parkinson’s Disease Dementia.
Objective: Currently there are no disease-treatments for Synucleinopathies including Parkinson’s disease dementia (PDD). Our objective is to use Ambroxol to target GBA/Glucocerebrosidase to treat PDD.…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 7
- Next Page »